<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Gen Pract</journal-id><journal-id journal-id-type="iso-abbrev">Br J Gen Pract</journal-id><journal-id journal-id-type="publisher-id">bjgp</journal-id><journal-title-group><journal-title>The British Journal of General Practice</journal-title></journal-title-group><issn pub-type="ppub">0960-1643</issn><issn pub-type="epub">1478-5242</issn><publisher><publisher-name>Royal College of General Practitioners</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29970394</article-id><article-id pub-id-type="pmc">6058619</article-id><article-id pub-id-type="doi">10.3399/bjgp18X697937</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Impact of a single eGFR and eGFR-estimating equation on chronic kidney disease reclassification: a cohort study in primary care</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hirst</surname><given-names>Jennifer A</given-names></name><degrees>MSc, DPhil</degrees><role>Senior primary care researcher</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Montes</surname><given-names>Maria DLA Vazquez</given-names></name><degrees>MSc, PhD</degrees><role>Senior statistician</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>Clare J</given-names></name><degrees>MA, MPH, PhD, FRCGP</degrees><role>NIHR academic clinical lecturer</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ord&#x000f3;&#x000f1;ez-Mena</surname><given-names>Jos&#x000e9; M</given-names></name><degrees>MSc, Dr. Sc. Hum.</degrees><role>Medical statistician</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ogburn</surname><given-names>Emma</given-names></name><degrees>PhD</degrees><role>Clinical trials unit operational director</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Vanshika</given-names></name><degrees>MSc</degrees><role>Clinical trial manager</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Shine</surname><given-names>Brian</given-names></name><degrees>MD, FRCPath</degrees><role>Consultant chemical pathologist</role></contrib><aff>Oxford University Hospitals Biochemistry Department, John Radcliffe Hospital, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>James</surname><given-names>Tim</given-names></name><degrees>PhD</degrees><role>Biomedical scientist and laboratory manager</role></contrib><aff>Oxford University Hospitals Biochemistry Department, John Radcliffe Hospital, Oxford.</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hobbs</surname><given-names>FD Richard</given-names></name><degrees>MA, FRCP (London), FRCP (Edin), FESC, FRCGP, FMedSci</degrees><role>Head of department</role></contrib><aff>Nuffield Department of Primary Care Health Sciences, Oxford.</aff></contrib-group><author-notes><corresp><bold>Address for correspondence</bold> Jennifer Hirst, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK. Email: <email>jennifer.hirst@phc.ox.ac.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>03</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>03</day><month>7</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>68</volume><issue>673</issue><fpage>e524</fpage><lpage>e530</lpage><history><date date-type="received"><day>23</day><month>2</month><year>2018</year></date><date date-type="rev-request"><day>15</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; British Journal of General Practice 2018</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This article is Open Access: CC BY 4.0 licence (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><sec><title>Background</title><p>Chronic kidney disease (CKD) is diagnosed using the estimated glomerular filtration rate (eGFR) and the urinary albumin:creatinine ratio (ACR). The eGFR is calculated from serum creatinine levels using the Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.</p></sec><sec><title>Aim</title><p>To compare the performance of one versus two eGFR/ACR measurements, and the impact of equation choice, on CKD diagnosis and classification.</p></sec><sec><title>Design and setting</title><p>Cohort study in primary care in the Thames Valley region of the UK.</p></sec><sec><title>Method</title><p>Data were from 485 participants aged &#x0003e;60 years in the Oxford Renal Cohort Study with at least two eGFR tests. The proportion of study participants diagnosed and classified into different CKD stages using one and two positive tests were compared. Prevalence of CKD diagnosis and classification by CKD stage were compared when eGFR was calculated using MDRD and CKD-EPI equations.</p></sec><sec><title>Results</title><p>Participants included in the analysis had a mean age of 72.1 (&#x000b1;6.8) years and 57.0% were female. Use of a single screening test overestimated the proportion of people with CKD by around 25% no matter which equation was used, compared with the use of two tests. The mean eGFR was 1.4 ml/min/1.73 m<sup>2</sup> (95% CI = 1.1 to 1.6) higher using the CKD-EPI equation compared with the MDRD equation. More patients were diagnosed with CKD when using the MDRD equation, compared with the CKD-EPI equation, once (64% versus 63%, respectively) and twice (39% versus 38%, respectively), and 16 individuals, all of who had CKD stages 2 or 3A with MDRD, were reclassified as having a normal urinary ACR when using the CKD-EPI equation.</p></sec><sec><title>Conclusion</title><p>Current guidance to use two eGFR measures to diagnose CKD remains appropriate in an older primary care population to avoid overdiagnosis. A change from MDRD to CKD-EPI equation could result in one in 12 patients with a CKD diagnosis with MDRD no longer having a diagnosis of CKD.</p></sec></abstract><kwd-group><kwd>chronic kidney diseases</kwd><kwd>CKD-EPI</kwd><kwd>eGFR</kwd><kwd>glomerular filtration rate</kwd><kwd>kidney failure, chronic</kwd><kwd>MDRD</kwd><kwd>overdiagnosis</kwd><kwd>renal insufficiency, chronic</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Chronic kidney disease (CKD) is a global health problem associated with high levels of morbidity and mortality.<xref rid="b1" ref-type="bibr">1</xref><sup>&#x02013;</sup><xref rid="b3" ref-type="bibr">3</xref> The prevalence of CKD is increasing worldwide,<xref rid="b4" ref-type="bibr">4</xref> with current estimates being approximately 13% in the general population.<xref rid="b5" ref-type="bibr">5</xref> There is an age-related decline in renal function, with the largest burden in those aged &#x0003e;60 years.<xref rid="b6" ref-type="bibr">6</xref><sup>&#x02013;</sup><xref rid="b8" ref-type="bibr">8</xref></p><p>CKD is diagnosed using measures of kidney damage or function, including the increased urinary albumin:creatinine ratio (ACR) or decreased glomerular filtration rate (GFR), usually estimated from serum creatinine levels. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is the global standard for estimating GFR, although previously the Modification of Diet in Renal Disease (MDRD) equation was most commonly used.<xref rid="b9" ref-type="bibr">9</xref><sup>,</sup><xref rid="b10" ref-type="bibr">10</xref> A description of both equations is available from the authors on request. Adoption of the CKD-EPI equation in the UK was recommended by the National Institute for Health and Care Excellence in 2014<xref rid="b10" ref-type="bibr">10</xref> and the target of nationwide roll-out by April 2017 was set by the Association for Clinical Biochemistry and Laboratory Medicine in 2016.<xref rid="b11" ref-type="bibr">11</xref> Despite this, many laboratories have not yet converted, and still use, the MDRD equation to test for CKD.</p><p>CKD is diagnosed if urinary ACR is &#x02265;3 mg/mmol or the estimated glomerular filtration rate (eGFR) is &#x0003c;60 ml/min/1.73 m<sup>2</sup> on two occasions at least 90 days apart.<xref rid="b10" ref-type="bibr">10</xref><sup>,</sup><xref rid="b12" ref-type="bibr">12</xref> Stages of CKD range from stage 1 in those with normal eGFR but in whom renal damage is present (indicated by an elevated ACR), to stage 5, which constitutes kidney failure. (The thresholds of each CKD stage are available from the authors on request.)<xref rid="b10" ref-type="bibr">10</xref><sup>,</sup><xref rid="b12" ref-type="bibr">12</xref></p><p>Prevalence estimates of CKD can vary widely, depending on whether they are based on a single eGFR (which may result in a false positive rate of 30&#x02013;50%) or two tests (as recommended by guidelines set by Kidney Disease: Improving Global Outcomes [KDIGO]).<xref rid="b13" ref-type="bibr">13</xref><sup>,</sup><xref rid="b14" ref-type="bibr">14</xref> Furthermore, introduction of the CKD-EPI equation may result in reduced prevalence of CKD;<xref rid="b13" ref-type="bibr">13</xref> however, despite CKD often being managed by primary care, data from primary care populations is lacking.</p><p>This study reports findings from an analysis of data from the Oxford Renal Cohort Study (OxRen),<xref rid="b15" ref-type="bibr">15</xref> which recruited 3205 participants aged &#x0003e;60 years from primary care within the Thames Valley region of the UK. It details how CKD prevalence estimates and stages of CKD differ, depending on whether a single eGFR or two measures (as recommended by KDIGO guidelines) are used, and compares proportions of patients classified in each CKD stage when the CKD-EPI equation versus the MDRD equation is used.</p><boxed-text position="float"><sec><title>How this fits in</title><p>Diagnosis of chronic kidney disease (CKD) is based on two screening tests; reports have suggested that a single test could overestimate the prevalence of CKD by as much as 50%. This study has found that a single test overestimated CKD by 25% in an older primary care population, suggesting that a second screening test is clinically appropriate. As laboratories move from using the Modification of Diet in Renal Disease (MDRD) equation to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to estimate glomerular filtration rate, some people will no longer have a CKD diagnosis. This study found that 8% of people with a CKD diagnosis based on use of the MDRD equation will be reclassified as not having CKD if the CKD-EPI equation is used.</p></sec></boxed-text></sec><sec sec-type="methods"><title>METHOD</title><p>Data were used from 485 participants in the OxRen study who had two CKD screening tests, which had been conducted between 90 days and 2 years (730 days) apart. The remainder of study participants had either a single screening test or the second test fell outside the time limits. All samples were analysed across two laboratories using identical ACR and isotope dilution mass spectrometry (IDMS)-traceable creatinine assays, and reported the MDRD eGFR. Both samples for each patient were processed in the same laboratory.</p><p>The MDRD eGFR, patient age (at each screening test), sex, and ethnicity were used to calculate the CKD-EPI eGFR. The mean patient age was used for those for whom age was missing (<italic>n</italic> = 30, 6.2%) and, as the recruitment area for OxRen has a majority white population, white ethnicity was allocated to 30 patients (6.2%) for whom no ethnicity was recorded. Those for whom no data regarding their sex were recorded (<italic>n</italic> = 9, 1.9%) were excluded. People with missing ACR results (<italic>n</italic> = 8 [1.6%], and <italic>n</italic> = 6 [1.2%] in first and second screening test respectively) were included in the analysis, and the ACR was assumed to be &#x0003e;3 mg/mmol. The majority of participants included in this cohort had two screening tests because the first screening test suggested a positive CKD diagnosis. On this basis the higher ACR was used. The same assumptions were made for the first and second tests. Results were compared with eGFR results calculated directly from serum creatinine levels in a subset of patients for whom this was available. Sensitivity analyses were carried out to explore the impact of these approximations.</p><p>Numbers of patients diagnosed with CKD, sex, age, ethnicity, and mean and standard deviation (SD) time between screening visits were tabulated. The mean and SDs of the eGFR calculated using the MDRD and CKD-EPI equations were summarised by using the first measure alone, the second measure alone, and the mean of both measures. Proportions of patients diagnosed with CKD using a single eGFR/ACR screening test and two positive eGFR/ACR screening tests using the MDRD and CKD-EPI equations were tabulated.</p><p>Using both equations, the numbers of patients classified into each CKD stage using a single test and two eGFR measures (the second of two positive measures, the higher of two positive eGFRs, and the mean of two positive eGFRs) were calculated. Results were tabulated to:
<list list-type="bullet"><list-item><p>show how patients were reclassified into different CKD stages using both the MDRD and CKD-EPI equations and two measures, instead of one, were used to calculate eGFRs; and</p></list-item><list-item><p>compare diagnoses and reclassification of CKD stage when the CKD-EPI equation is used instead of the MDRD equation.</p></list-item></list></p><p>Scatter plots were used to compare the first and second eGFR measures for both equations. Bland&#x02013;Altman plots<xref rid="b16" ref-type="bibr">16</xref> were used to compare the mean difference between the first and second measures with the mean of both measures. The eGFR, calculated using the CKD-EPI and MDRD equations for the first and second measure for each patient, were plotted to show agreement between equations. A multinomial logistic regression analysis was used to examine the association between age, sex, and change in CKD stage when moving from the MDRD to the CKD-EPI equation. All analyses were carried out using StataCorp&#x02019;s Stata/SE version 14.</p></sec><sec sec-type="results"><title>RESULTS</title><p>Participants&#x02019; mean age was 72.1 (&#x000b1;6.8) years, 57.5% were female, and 98.9% of those with data had white ethnicity. The mean time between screening tests was 153 (&#x000b1;107) days (range 90&#x02013;728 days) (<xref rid="table1" ref-type="table">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><p>Description of cohort, <italic>n</italic> = 485</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="left" rowspan="1" colspan="1"><bold>Descriptor</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Data</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age in years at first test</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">72.1 (6.8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Range</td><td valign="top" align="center" rowspan="1" colspan="1">60.0&#x02013;93.2</td></tr><tr><td colspan="2" valign="top" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Sex</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Female, %</td><td valign="top" align="center" rowspan="1" colspan="1">57.5</td></tr><tr><td colspan="2" valign="top" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Time between tests in days</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">153 (107)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Median (IQR)</td><td valign="top" align="center" rowspan="1" colspan="1">112.5 (100&#x02013;147)</td></tr><tr><td colspan="2" valign="top" align="center" rowspan="1">
<hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Ethnicity, <italic>n</italic></bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;White</td><td valign="top" align="center" rowspan="1" colspan="1">449</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Mixed ethnicity</td><td valign="top" align="center" rowspan="1" colspan="1">4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Black</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="tfn1"><p><italic>IQR</italic> = <italic>interquartile range. SD</italic> = <italic>standard deviation.</italic></p></fn></table-wrap-foot></table-wrap><p>When using the second measure alone, the mean eGFR generated when using the CKD-EPI equation was 1.4 ml/min/1.73 m<sup>2</sup> (95% confidence interval [CI] = 1.1 to 1.6) higher than that generated when using the MDRD equation: 68.3 and 66.9ml/min/1.73m<sup>2</sup> for CKD-EPI and MDRD respectively (<xref rid="table2" ref-type="table">Table 2</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><p>Mean eGFR and CKD diagnosis based on single or duplicate measures using the MDRD and CKD-EPI equations</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1"/><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>MDRD equation, <italic>n</italic>= 485</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>CKD-EPI equation, <italic>n</italic>= 476<xref ref-type="table-fn" rid="tfn2"><sup>a</sup></xref></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFR (ml/min/1.73 m<sup>2</sup>) using first measure, mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">66.4 (12.2)</td><td valign="top" align="center" rowspan="1" colspan="1">67.5 (12.1)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFR (ml/min/1.73 m<sup>2</sup>) using second measure, mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">66.9 (11.9)</td><td valign="top" align="center" rowspan="1" colspan="1">68.3 (12.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">eGFR (ml/min/1.73 m<sup>2</sup>) using both measures, mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">66.6 (12.1)</td><td valign="top" align="center" rowspan="1" colspan="1">67.9 (12.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Classified as having CKD based on first eGFR alone, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">311 (64)</td><td valign="top" align="center" rowspan="1" colspan="1">301 (63)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Classified as having CKD based on two positive eGFRs, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">190 (39)</td><td valign="top" align="center" rowspan="1" colspan="1">182 (38)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Incorrectly classified using a single measure, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">121 (25)</td><td valign="top" align="center" rowspan="1" colspan="1">119 (25)</td></tr></tbody></table><table-wrap-foot><fn id="tfn2"><label>a</label><p><italic>Nine patients excluded as sex missing. CKD</italic> = <italic>chronic kidney disease. CKD-EPI</italic> = <italic>Chronic Kidney Disease Epidemiology Collaboration. eGFR</italic> = <italic>estimated glomerular filtration rate. MDRD</italic> = <italic>Modification of Diet in Renal Disease. SD</italic> = <italic>standard deviation.</italic></p></fn></table-wrap-foot></table-wrap><p>The number of patients diagnosed with CKD using each equation and a single test or two positive eGFR/ACR measures are shown in <xref rid="table2" ref-type="table">Table 2</xref>. The MDRD and CKD-EPI equations classify similar numbers of patients as having CKD whether the first eGFR alone or two measures are used: 64% of patients with the MDRD equation versus 63% using the CKD-EPI equation for a single screening test, and 39% (MDRD equation) and 38% (CKD-EPI equation) when using two positive tests. Both equations incorrectly classified approximately 25% using a single test. Results were similar in sensitivity analyses using only those with complete data (available from the authors on request) and laboratory-reported serum creatinine levels (data not shown).</p><p>The number of participants classified into different CKD stages using a single and two positive eGFR/ACR measures for both equations are shown in <xref rid="table3" ref-type="table">Table 3</xref>. Using the second of two positive measures, fewer patients were classified as having stage 1 CKD and more as having stage 2 CKD with the CKD-EPI equation than with the MDRD equation (2% versus 7% and 50% versus 45% respectively). Using the CKD-EPI and the MDRD equations, similar proportions of patients were classified as having stage 3A CKD (40% versus 41%) and stage 3B CKD (8% versus 7% respectively).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><p>Patients categorised by CKD stage using a single and two eGFR measures for the MDRD and CKD-EPI equations</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" rowspan="3" align="left" colspan="1"><bold>CKD stage</bold></th><th colspan="4" valign="bottom" align="center" rowspan="1"><bold>MDRD equation</bold></th><th colspan="4" valign="bottom" align="center" rowspan="1"><bold>CKD-EPI equation</bold></th></tr><tr><th valign="bottom" rowspan="2" align="center" colspan="1"><bold>Single eGFR (<italic>n</italic>= 311), <italic>n</italic> (%)</bold></th><th colspan="3" valign="bottom" align="center" rowspan="1"><bold>Two eGFRs, <italic>n</italic>= 190</bold></th><th valign="bottom" rowspan="2" align="center" colspan="1"><bold>Single eGFR (<italic>n</italic>= 301), <italic>n</italic> (%)</bold></th><th colspan="3" valign="bottom" align="center" rowspan="1"><bold>Two eGFRs, <italic>n</italic>= 182</bold></th></tr><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Second eGFR, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Highest eGFR, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Mean of both eGFRs, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Second eGFR, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Highest eGFR, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Mean of both eGFRs, <italic>n</italic> (%)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage 1</td><td valign="top" align="center" rowspan="1" colspan="1">41 (13)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (11)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (6)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage 2</td><td valign="top" align="center" rowspan="1" colspan="1">142 (46)</td><td valign="top" align="center" rowspan="1" colspan="1">85 (45)</td><td valign="top" align="center" rowspan="1" colspan="1">91 (48)</td><td valign="top" align="center" rowspan="1" colspan="1">96 (51)</td><td valign="top" align="center" rowspan="1" colspan="1">166 (55)</td><td valign="top" align="center" rowspan="1" colspan="1">91 (50)</td><td valign="top" align="center" rowspan="1" colspan="1">100 (55)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (54)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage 3A</td><td valign="top" align="center" rowspan="1" colspan="1">115 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">77 (41)</td><td valign="top" align="center" rowspan="1" colspan="1">70 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">71 (37)</td><td valign="top" align="center" rowspan="1" colspan="1">102 (34)</td><td valign="top" align="center" rowspan="1" colspan="1">72 (40)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (36)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (36)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage 3B</td><td valign="top" align="center" rowspan="1" colspan="1">13 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (8)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage 4</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stage 5</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="tfn3"><p><italic>CKD</italic> = <italic>chronic kidney disease. CKD-EPI</italic> = <italic>Chronic Kidney Disease Epidemiology Collaboration. eGFR</italic> = <italic>estimated glomerular filtration rate. MDRD</italic> = <italic>Modification of Diet in Renal Disease.</italic></p></fn></table-wrap-foot></table-wrap><p>Results for reclassification of CKD stage from a single to two positive eGFRs (using the second value) for both equations are presented in <xref rid="table4" ref-type="table">Table 4</xref>. The proportion of patients who remained in the same category with two measures increased as the CKD stage of the first test increased for both equations; fewer people were reclassified as having normal urinary ACR if the first test indicated stage 3B CKD. Overall, using the MDRD equation and two eGFR/ACR measures instead of one resulted in 137 people (44%) moving to a lower CKD stage or being classified as having a normal urinary ACR, 22 (7%) moving to a higher CKD stage, and 152 (49%) remaining in the same CKD stage. When using the CKD-EPI equation and the second of two positive measures instead of a single eGFR, 127 people (42%) moved to a lower CKD stage or were reclassified as having a normal urinary ACR, 19 (6%) moved to a higher CKD stage, and 155 (51%) remained diagnosed with the same CKD stage.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><p>Reclassification of patients&#x02019; CKD stage when moving from a single test to the second of two eGFR measures<xref ref-type="table-fn" rid="tfn4"><sup>a</sup></xref></p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" rowspan="3" align="left" colspan="1"><bold>CKD stage at first test</bold></th><th colspan="6" valign="bottom" align="center" rowspan="1"><bold>MDRD equation, <italic>n</italic>= 311</bold></th><th colspan="6" valign="bottom" align="center" rowspan="1"><bold>CKD-EPI equation, <italic>n</italic>= 301</bold></th></tr><tr><th valign="bottom" rowspan="2" align="center" colspan="1"><bold>First, eGFR <italic>n</italic>= 311, <italic>n</italic></bold></th><th colspan="5" valign="bottom" align="center" rowspan="1"><bold>CKD stage at follow-up eGFR</bold></th><th valign="bottom" rowspan="2" align="center" colspan="1"><bold>First eGFR, <italic>n</italic>= 301, <italic>n</italic> (%)</bold></th><th colspan="5" valign="bottom" align="center" rowspan="1"><bold>CKD stage at follow-up eGFR</bold></th></tr><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Normal urinary ACR, <italic>n</italic>= 121, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 1, <italic>n</italic>= 14, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 2, <italic>n</italic>= 85, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 3A, <italic>n</italic>= 77, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 3B, <italic>n</italic>= 14, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Normal urinary ACR, <italic>n</italic>= 119, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 1, <italic>n</italic>= 4, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 2, <italic>n</italic>= 91, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 3A, <italic>n</italic>= 72, <italic>n</italic> (%)</bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 3B, <italic>n</italic>= 15, <italic>n</italic> (%)</bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Stage 1</bold></td><td valign="top" align="center" rowspan="1" colspan="1">41</td><td valign="top" align="center" rowspan="1" colspan="1">25 (61)</td><td valign="top" align="center" rowspan="1" colspan="1">10<xref ref-type="table-fn" rid="tfn5"><sup>b</sup></xref> (24)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">19</td><td valign="top" align="center" rowspan="1" colspan="1">12 (63)</td><td valign="top" align="center" rowspan="1" colspan="1">4<xref ref-type="table-fn" rid="tfn5"><sup>b</sup></xref> (21)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Stage 2</bold></td><td valign="top" align="center" rowspan="1" colspan="1">142</td><td valign="top" align="center" rowspan="1" colspan="1">56 (39)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">70<xref ref-type="table-fn" rid="tfn5"><sup>b</sup></xref> (49)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">166</td><td valign="top" align="center" rowspan="1" colspan="1">71 (43)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">83<xref ref-type="table-fn" rid="tfn5"><sup>b</sup></xref> (50)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Stage 3A</bold></td><td valign="top" align="center" rowspan="1" colspan="1">115</td><td valign="top" align="center" rowspan="1" colspan="1">39 (34)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">63<xref ref-type="table-fn" rid="tfn5"><sup>b</sup></xref> (55)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (3)</td><td valign="top" align="center" rowspan="1" colspan="1">102</td><td valign="top" align="center" rowspan="1" colspan="1">35 (34)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">58<xref ref-type="table-fn" rid="tfn5"><sup>b</sup></xref> (57)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Stage 3B</bold></td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="center" rowspan="1" colspan="1">1 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (23)</td><td valign="top" align="center" rowspan="1" colspan="1">9<xref ref-type="table-fn" rid="tfn5"><sup>b</sup></xref> (69)</td><td valign="top" align="center" rowspan="1" colspan="1">13<xref ref-type="table-fn" rid="tfn6"><sup>c</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">1 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (23)</td><td valign="top" align="center" rowspan="1" colspan="1">9<xref ref-type="table-fn" rid="tfn5"><sup>b</sup></xref> (69)</td></tr></tbody></table><table-wrap-foot><fn id="tfn4"><label>a</label><p>Percentages are presented across rows representing those reclassified after the second measure for each stage of CKD, and separately for MDRD and CKD-EPI.</p></fn><fn id="tfn5"><label>b</label><p>Numbers of patients for whom the CKD stage did not change.</p></fn><fn id="tfn6"><label>c</label><p>One patient was Stage 4 at the first test and stage 3B (100%) after the second test. ACR = albumin:creatinine ratio. CKD = chronic kidney disease. CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration. eGFR = estimated glomerular filtration rate. MDRD = Modification of Diet in Renal Disease.</p></fn></table-wrap-foot></table-wrap><p>The numbers of participants classified into different CKD stages when the eGFR was calculated using the CKD-EPI instead of the MDRD equation are shown in <xref rid="table5" ref-type="table">Table 5</xref>. When the CKD-EPI equation was used, the classified CKD stage remained the same for the majority of individuals; however, 18 of those diagnosed as having CKD when measured using the MDRD equation moved to a lower CKD stage or were classified as having normal kidney function, and 15 were diagnosed with a higher stage of CKD. Overall, 17% of those classified into stages 1&#x02013;3B using the MDRD equation were reclassified when using the CKD-EPI equation &#x02014; this included 14 patients who were reclassified from stage 3A to normal kidney function (non-CKD) and eight patients who were reclassified from having normal kidney function to having stage 3A CKD.</p><table-wrap id="table5" position="float"><label>Table 5.</label><caption><p>Reclassification of CKD stage when moving from the MDRD to the CKD-EPI equation using the second eGFR/ACR result after a positive first screening, <italic>n</italic> = 476<xref ref-type="table-fn" rid="tfn7"><sup>a</sup></xref></p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="bottom" rowspan="2" align="left" colspan="1"><bold>CKD stage based on MDRD equation</bold></th><th valign="bottom" rowspan="2" align="center" colspan="1"><bold><italic>n</italic></bold></th><th colspan="5" valign="bottom" align="center" rowspan="1"><bold>CKD stage based on CKD-EPI equation</bold></th></tr><tr><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Normal urinary ACR, <italic>n</italic>= 294, <italic>n</italic></bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 1, <italic>n</italic>= 4, <italic>n</italic></bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 2, n = 91, <italic>n</italic></bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 3A, <italic>n</italic>= 72, <italic>n</italic></bold></th><th valign="bottom" align="center" rowspan="1" colspan="1"><bold>Stage 3B, <italic>n</italic>= 15, <italic>n</italic></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Normal urinary ACR</bold></td><td valign="top" align="center" rowspan="1" colspan="1">286</td><td valign="top" align="center" rowspan="1" colspan="1">278<xref ref-type="table-fn" rid="tfn8"><sup>b</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Stage 1</bold></td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">4<xref ref-type="table-fn" rid="tfn8"><sup>b</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Stage 2</bold></td><td valign="top" align="center" rowspan="1" colspan="1">85</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">79<xref ref-type="table-fn" rid="tfn8"><sup>b</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Stage 3A</bold></td><td valign="top" align="center" rowspan="1" colspan="1">77</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">60<xref ref-type="table-fn" rid="tfn8"><sup>b</sup></xref></td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Stage 3B</bold></td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">14<xref ref-type="table-fn" rid="tfn8"><sup>b</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn7"><label>a</label><p>Nine patients excluded as sex missing.</p></fn><fn id="tfn8"><label>b</label><p><italic>Numbers of patients for whom the CKD stage did not change. ACR</italic> = <italic>albumin:creatinine ratio. CKD</italic> = <italic>chronic kidney disease. CKD-EPI</italic> = <italic>Chronic Kidney Disease Epidemiology Collaboration. eGFR</italic> = <italic>estimated glomerular filtration rate. MDRD</italic> = <italic>Modification of Diet in Renal Disease.</italic></p></fn></table-wrap-foot></table-wrap><p>Correlation plots between the first and second eGFR measures for both equations are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. The regression analysis showed similar agreement between the first and second measures using the MDRD equation (<italic>r</italic><sup>2</sup> = 0.645) compared with the CKD-EPI equation (<italic>r</italic><sup>2</sup> = 0.639). Bland&#x02013;Altman plots showed good agreement between the mean difference in the eGFR between the first and second measurement versus the mean of two measurements for the MDRD and CKD-EPI equations. On average, the first measure was higher than the second measure for each equation (data available from the authors on request). The CKD-EPI eGFR plotted against the MDRD eGFR for the first and second eGFR measures showed overall agreement (data available from the authors on request).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><p><bold><italic>The second eGFR plotted against the first eGFR measures estimated using the MDRD and CKD-EPI equations. CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration. eGFR = estimated glomerular filtration rate. MDRD = Modification of Diet in Renal Disease.</italic></bold></p></caption><graphic xlink:href="bjgpAug-2018-68-673-e524-OA"/></fig><p>The multinomial logistic regression analysis found a statistically significant association between age and reclassification of CKD stage when moving from the MDRD to the CKD-EPI equation (data not shown). An increase of 1 year in age is associated with a 7% lower risk of being reclassified to a lower CKD stage with the CKD-EPI equation compared with the CKD stage remaining the same (relative risk ratio [RRR] 0.93, 95% CI = 0.85 to 1.01), and a 12% higher risk of being reclassified to a higher CKD stage (RRR 1.12, 95% CI = 1.06 to 1.19). Multinomial logistic regression directly compared those with an increase in CKD stage with those with a decrease in CKD stage. This confirmed that participants were 20% more likely to be reclassified to a higher stage using the CKD-EPI equation for each increase in year of age than they were to be reclassified to a lower stage, compared with no change in CKD stage between equations.</p><p>Males were 3.99 times (95% CI = 1.50 to 10.59) more likely to be reclassified to a higher CKD stage than females when the CKI-EPI equation was used instead of the MDRD equation (data not shown).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><sec sec-type="conclusions"><title>Summary</title><p>This analysis has found that, in an older primary care population, a single CKD screening test overestimates the number of people diagnosed with CKD by around 25%, compared with two tests. The mean eGFR was higher using the CKD-EPI equation compared with the MDRD equation, indicating that fewer patients will have a diagnosis of CKD when laboratories move to reporting eGFR using the CKD-EPI equation.</p><p>Most people in the cohort had stage 2 CKD, followed by those with stage 1 CKD, indicating that they had an abnormal ACR result but normal or mildly reduced eGFR. These people would retain their CKD diagnosis regardless of the equation used. Most participants whose first CKD screening test indicated a CKD diagnosis that was not confirmed in the follow-up test were, using the first test alone, initially classified as having stage 1&#x02013;3A CKD; this suggests that the reclassification stems from variability in the ACR as well as serum creatinine levels. Reclassification was most marked for those with stage 3A CKD using the MDRD equation; in total, 18% of this group were reclassified as having normal urinary ACR using the CKD-EPI equation (<xref rid="table5" ref-type="table">Table 5</xref>) &#x02014; all had normal ACR results and the diagnosis was based solely on reduced MDRD eGFR. Prevalence of CKD was 39% in this pre-selected cohort with two ACR/eGFR tests.</p></sec><sec><title>Strengths and limitations</title><p>To the authors&#x02019; knowledge, this is the largest analysis to compare CKD diagnoses and reclassification, based on single and twice-conducted screening tests in an older population in primary care. The study presented here is unique, as far as the authors are aware, in reporting results from an older primary care population. However, in carrying out this analysis, it was only possible to access eGFRs that had been calculated using the MDRD equation. Using the available data on age and ethnicity, the authors were able to calculate the eGFR using the CKD-EPI equation, but some assumptions had to be made to use the full dataset. The impact of these estimations have been assessed in a sub-sample of patients with creatinine results and in a sensitivity analysis, which showed similar results.</p><p>A further limitation is that the cohort was mainly of white ethnicity and so may not be generalisable to the general UK population.</p><p>It is acknowledged that both equations used to calculate the eGFR in this analysis exhibit some bias relative to measuring GFR;<xref rid="b17" ref-type="bibr">17</xref> results may differ if the GFR is measured using gold-standard methods, which involves using radioisotope or iothalamate methods and taking multiple blood or urine samples.<xref rid="b18" ref-type="bibr">18</xref></p></sec><sec><title>Comparison with existing literature</title><p>Previous studies have suggested that the prevalence of CKD may be overestimated by 30&#x02013;50% using a single eGFR compared with two positive measures.<xref rid="b13" ref-type="bibr">13</xref><sup>,</sup><xref rid="b14" ref-type="bibr">14</xref><sup>,</sup><xref rid="b19" ref-type="bibr">19</xref> However, not all studies used the KDIGO criteria for diagnosis,<xref rid="b8" ref-type="bibr">8</xref> or studied populations with low CKD prevalence.<xref rid="b14" ref-type="bibr">14</xref><sup>,</sup><xref rid="b20" ref-type="bibr">20</xref> Prevalence of CKD was 39% in this pre-selected cohort with two ACR/eGFR tests.</p><p>The finding presented here, that the CKD-EPI equation gave a higher mean eGFR and reduced the prevalence of CKD compared with the MDRD equation, has been reported by other researchers.<xref rid="b7" ref-type="bibr">7</xref><sup>,</sup><xref rid="b13" ref-type="bibr">13</xref><sup>,</sup><xref rid="b21" ref-type="bibr">21</xref><sup>,</sup><xref rid="b22" ref-type="bibr">22</xref> In this study, it was found that 17% of patients were reclassified using the CKD-EPI rather than the MDRD equation; this is similar to numbers from a previous report,<xref rid="b23" ref-type="bibr">23</xref> in which reclassification to a lower CKD stage was associated with fewer adverse outcomes.</p><p>Previous research has found that using the CKD-EPI equation increased CKD prevalence compared with use of the MDRD equation;<xref rid="b24" ref-type="bibr">24</xref> this may be an artefact of participant age and prevalence or severity of CKD in the populations studied, or the relative accuracy of the creatinine method. Using the CKD-EPI equation instead of the MDRD equation may decrease the proportion of younger patients (&#x0003c;60 years) diagnosed with CKD, but the reverse may be true in some older patient groups.<xref rid="b7" ref-type="bibr">7</xref><sup>,</sup><xref rid="b22" ref-type="bibr">22</xref> The regression analysis presented here found that older age and male sex were associated with reclassification to a higher CKD stage using the CKD-EPI equation.</p><p>A recent meta-analysis has shown that the CKD-EPI equation gives a better eGFR than the MDRD equation, particularly in patients with the highest kidney function.<xref rid="b17" ref-type="bibr">17</xref> Although the age of the OxRen cohort was &#x0003e;60 years, none of the patients had severely decreased kidney function in whom the MDRD equation may perform better.<xref rid="b7" ref-type="bibr">7</xref><sup>,</sup><xref rid="b17" ref-type="bibr">17</xref></p><p>The strong association between reclassification of CKD stage in males may be due to the effect of muscle mass on creatinine-based measures,<xref rid="b25" ref-type="bibr">25</xref> which could be avoided with cystatin C-based equations.<xref rid="b25" ref-type="bibr">25</xref><sup>,</sup><xref rid="b26" ref-type="bibr">26</xref></p></sec><sec sec-type="discussion"><title>Implications for practice</title><p>This study has found that a single eGFR/ACR test would result in an unacceptably high rate of overdiagnosis of CKD, and confirms that current recommendations to base CKD diagnoses on two positive tests &#x02014; thereby allowing for biological and analytical variability &#x02014; are appropriate in primary care.</p><p>As laboratories move from using the MDRD to the CKD-EPI equation, further consideration is needed to determine how those patients who had a CKD diagnosis but fall below the CKD threshold with the new equation should be treated and followed up as there is no guidance on how GPs should respond or how this could be communicated to patients. If these patients retain their CKD diagnoses, despite no longer meeting the diagnostic criteria, they may receive unnecessary monitoring, treatment, and interventions.</p><p>Fewer than 1% of patients with stage 3A CKD are reported to go on to develop end-stage renal disease during 8 years of follow-up<xref rid="b27" ref-type="bibr">27</xref> and there have been suggestions that definitions of CKD may need to change, particularly for those people who have stage 3A CKD without albuminuria.<xref rid="b28" ref-type="bibr">28</xref> Although kidney function declines with age and decreasing eGFR is associated with increased mortality,<xref rid="b29" ref-type="bibr">29</xref> many older people are diagnosed with CKD without being at high risk of adverse outcomes; it has, therefore, been suggested that using different cut-offs for older people may be appropriate.<xref rid="b30" ref-type="bibr">30</xref> On this basis, it is likely that the move to the CKD-EPI equation will result in more-appropriate CKD classification based on the risk of future adverse outcomes<xref rid="b23" ref-type="bibr">23</xref> and comparison with measured GFR<xref rid="b17" ref-type="bibr">17</xref> for this population.</p><p>The time interval between tests may also affect the agreement between the tests. KDIGO defines chronic CKD as a duration &#x0003e;3 months, but this time interval was selected arbitrarily.<xref rid="b12" ref-type="bibr">12</xref> If the minimum length of time between CKD screenings tests is extended to 12 months, the prevalence of CKD stages 3&#x02013;4 could decrease by 37%;<xref rid="b31" ref-type="bibr">31</xref> this may have implications for the definition of chronicity of CKD in future. In the analysis presented here, the KDIGO definition of a minimum of 3 months has been accepted, but some tests were up to 2 years apart. On this basis, this study has found that current guidance to use two eGFR measures to diagnose CKD remains appropriate in an older primary care population to avoid overdiagnosis.</p></sec></sec></body><back><notes><sec><title>Funding</title><p>Jennifer Hirst is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford; Clare Taylor is funded by an NIHR Academic Clinical Lectureship; FD Richard Hobbs acknowledges part-support from the NIHR School for Primary Care Research, the NIHR Collaboration for Leadership in Applied Research in Health and Care, Oxford, and the NIHR Oxford Biomedical Research Centre.</p></sec><sec><title>Ethical approval</title><p>OxRen received ethical approval from South Central, Oxford B Research Ethics Committee (Ref: 13/SC/0020).</p></sec><sec><title>Provenance</title><p>Freely submitted; externally peer reviewed.</p></sec><sec><title>Competing interests</title><p>The authors have declared no competing interests.</p></sec><sec><title>Discuss this article</title><p>Contribute and read comments about this article: <bold><ext-link ext-link-type="uri" xlink:href="bjgp.org/letters">bjgp.org/letters</ext-link></bold></p></sec></notes><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keith</surname><given-names>DS</given-names></name><name><surname>Nichols</surname><given-names>GA</given-names></name><name><surname>Gullion</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization</article-title><source>Arch Intern Med</source><year>2004</year><volume>164</volume><issue>6</issue><fpage>659</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">15037495</pub-id></element-citation></ref><ref id="b2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gansevoort</surname><given-names>RT</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>van der Velde</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts</article-title><source>Kidney Int</source><year>2011</year><volume>80</volume><issue>1</issue><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">21289597</pub-id></element-citation></ref><ref id="b3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Chronic Kidney Disease Prognosis Consortium</collab><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>van der Velde</surname><given-names>M</given-names></name><name><surname>Astor</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis</article-title><source>Lancet</source><year>2010</year><volume>375</volume><issue>9731</issue><fpage>2073</fpage><lpage>2081</lpage><pub-id pub-id-type="pmid">20483451</pub-id></element-citation></ref><ref id="b4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jager</surname><given-names>KJ</given-names></name><name><surname>Fraser</surname><given-names>SDS</given-names></name></person-group><article-title>The ascending rank of chronic kidney disease in the global burden of disease study.</article-title><source>Nephrol Dial Transplant</source><year>2017</year><volume>32</volume><issue>Suppl 2</issue><fpage>ii121</fpage><lpage>ii128</lpage><pub-id pub-id-type="pmid">28201666</pub-id></element-citation></ref><ref id="b5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>NR</given-names></name><name><surname>Fatoba</surname><given-names>ST</given-names></name><name><surname>Oke</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Global prevalence of chronic kidney disease: a systematic review and meta-analysis</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>7</issue><fpage>e0158765</fpage><pub-id pub-id-type="pmid">27383068</pub-id></element-citation></ref><ref id="b6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lusignan</surname><given-names>S</given-names></name><name><surname>Tomson</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>K</given-names></name><etal/></person-group><article-title>Creatinine fluctuation has a greater effect than the formula to estimate glomerular filtration rate on the prevalence of chronic kidney disease</article-title><source>Nephron Clin Pract</source><year>2011</year><volume>117</volume><issue>3</issue><fpage>c213</fpage><lpage>c224</lpage><pub-id pub-id-type="pmid">20805694</pub-id></element-citation></ref><ref id="b7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Callaghan</surname><given-names>CA</given-names></name><name><surname>Shine</surname><given-names>B</given-names></name><name><surname>Lasserson</surname><given-names>DS</given-names></name></person-group><article-title>Chronic kidney disease: a large-scale population-based study of the effects of introducing the CKD-EPI formula for eGFR reporting</article-title><source>BMJ Open</source><year>2011</year><volume>1</volume><issue>2</issue><fpage>e000308</fpage></element-citation></ref><ref id="b8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Prevalence of chronic kidney disease in the United States</article-title><source>JAMA</source><year>2007</year><volume>298</volume><issue>17</issue><fpage>2038</fpage><lpage>2047</lpage><pub-id pub-id-type="pmid">17986697</pub-id></element-citation></ref><ref id="b9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><etal/></person-group><article-title>A new equation to estimate glomerular filtration rate</article-title><source>Ann Int Med</source><year>2009</year><volume>150</volume><issue>9</issue><fpage>604</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">19414839</pub-id></element-citation></ref><ref id="b10"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence.</collab></person-group><source>Chronic kidney disease in adults: assessment and management. CG182.</source><year>2014</year><publisher-loc>London</publisher-loc><publisher-name>NICE</publisher-name><comment><ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/cg182">https://www.nice.org.uk/guidance/cg182</ext-link> (accessed 21 May 2018)</comment></element-citation></ref><ref id="b11"><label>11.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Association for Clinical Biochemistry and Laboratory Medicine</collab></person-group><article-title>A statement from the ACB and LIMS manufacturers regarding CKD-EPI issued 09th February 2016</article-title><comment><ext-link ext-link-type="uri" xlink:href="http://www.acb.org.uk/docs/default-source/documents/ckd-epi-statement-feb-2016-.pdf?sfvrsn=2">http://www.acb.org.uk/docs/default-source/documents/ckd-epi-statement-feb-2016-.pdf?sfvrsn=2</ext-link> (accessed 21 May 2018)</comment></element-citation></ref><ref id="b12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group 2012.</collab></person-group><article-title>KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.</article-title><source>Kidney Int Suppl</source><year>2013</year><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>150</lpage></element-citation></ref><ref id="b13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glassock</surname><given-names>RJ</given-names></name><name><surname>Warnock</surname><given-names>DG</given-names></name><name><surname>Delanaye</surname><given-names>P</given-names></name></person-group><article-title>The global burden of chronic kidney disease: estimates, variability and pitfalls</article-title><source>Nat Rev Nephrol</source><year>2017</year><volume>13</volume><issue>2</issue><fpage>104</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">27941934</pub-id></element-citation></ref><ref id="b14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottomley</surname><given-names>MJ</given-names></name><name><surname>Kalachik</surname><given-names>A</given-names></name><name><surname>Mevada</surname><given-names>C</given-names></name><etal/></person-group><article-title>Single estimated glomerular filtration rate and albuminuria measurement substantially overestimates prevalence of chronic kidney disease.</article-title><source>Nephron Clin Pract</source><year>2011</year><volume>117</volume><issue>4</issue><fpage>c348</fpage><lpage>c352</lpage><pub-id pub-id-type="pmid">20948233</pub-id></element-citation></ref><ref id="b15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>NR</given-names></name><name><surname>Lasserson</surname><given-names>D</given-names></name><name><surname>Fatoba</surname><given-names>S</given-names></name><etal/></person-group><article-title>The Oxford Renal (OxRen) cross-sectional study of chronic kidney disease in the UK</article-title><source>BMJ Open</source><year>2013</year><volume>3</volume><issue>12</issue><fpage>e004265</fpage></element-citation></ref><ref id="b16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Bland</surname><given-names>JM</given-names></name></person-group><article-title>Measurement in medicine: the analysis of method comparison studies</article-title><source>The Statistician</source><year>1983</year><volume>32</volume><fpage>307</fpage><lpage>317</lpage></element-citation></ref><ref id="b17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFadden</surname><given-names>EC</given-names></name><name><surname>Hirst</surname><given-names>JA</given-names></name><name><surname>Verbakel</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Systematic review and metaanalysis comparing the bias and accuracy of the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration equations in community-based populations</article-title><source>Clin Chem</source><year>2018</year><volume>64</volume><issue>3</issue><fpage>475</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">29046330</pub-id></element-citation></ref><ref id="b18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traynor</surname><given-names>J</given-names></name><name><surname>Mactier</surname><given-names>R</given-names></name><name><surname>Geddes</surname><given-names>CC</given-names></name><name><surname>Fox</surname><given-names>JG</given-names></name></person-group><article-title>How to measure renal function in clinical practice</article-title><source>BMJ (Clinical Research Ed)</source><year>2006</year><volume>333</volume><issue>7571</issue><fpage>733</fpage><lpage>737</lpage></element-citation></ref><ref id="b19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delanaye</surname><given-names>P</given-names></name><name><surname>Glassock</surname><given-names>RJ</given-names></name><name><surname>De Broe</surname><given-names>ME</given-names></name></person-group><article-title>Epidemiology of chronic kidney disease: think (at least) twice!</article-title><source>Clin Kidney J</source><year>2017</year><volume>10</volume><issue>3</issue><fpage>370</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">28617483</pub-id></element-citation></ref><ref id="b20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benghanem Gharbi</surname><given-names>M</given-names></name><name><surname>Elseviers</surname><given-names>M</given-names></name><name><surname>Zamd</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chronic kidney disease, hypertension, diabetes, and obesity in the adult population of Morocco: how to avoid &#x02018;over&#x02019;-and &#x02018;under&#x02019;-diagnosis of CKD.</article-title><source>Kidney Int</source><year>2016</year><volume>89</volume><issue>6</issue><fpage>1363</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">27165829</pub-id></element-citation></ref><ref id="b21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cristelli</surname><given-names>MP</given-names></name><name><surname>Cof&#x000e1;n</surname><given-names>F</given-names></name><name><surname>Rico</surname><given-names>N</given-names></name><etal/></person-group><article-title>Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis</article-title><source>BMC Nephrol</source><year>2017</year><volume>18</volume><issue>1</issue><fpage>58</fpage><pub-id pub-id-type="pmid">28183270</pub-id></element-citation></ref><ref id="b22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schold</surname><given-names>JD</given-names></name><name><surname>Navaneethan</surname><given-names>SD</given-names></name><name><surname>Jolly</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Implications of the CKD-EPI GFR estimation equation in clinical practice</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><issue>3</issue><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">21115622</pub-id></element-citation></ref><ref id="b23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Tonelli</surname><given-names>M</given-names></name><name><surname>Lloyd</surname><given-names>A</given-names></name><etal/></person-group><article-title>Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR</article-title><source>Am J Kid Dis</source><year>2012</year><volume>60</volume><issue>2</issue><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">22560843</pub-id></element-citation></ref><ref id="b24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>N</given-names></name><name><surname>Jakob</surname><given-names>O</given-names></name><name><surname>Gaedeke</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prevalence of reduced kidney function and albuminuria in older adults: the Berlin Initiative Study.</article-title><source>Nephrol Dail Transplant</source><year>2017</year><volume>32</volume><issue>6</issue><fpage>997</fpage><lpage>1005</lpage></element-citation></ref><ref id="b25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Inker</surname><given-names>LA</given-names></name></person-group><article-title>Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review</article-title><source>JAMA</source><year>2015</year><volume>313</volume><issue>8</issue><fpage>837</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">25710660</pub-id></element-citation></ref><ref id="b26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inker</surname><given-names>LA</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name></person-group><article-title>Estimated glomerular filtration rate from a panel of filtration markers: hope for increased accuracy beyond measured glomerular filtration rate?</article-title><source>Adv Chronic Kidney Dis</source><year>2018</year><volume>25</volume><issue>1</issue><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">29499889</pub-id></element-citation></ref><ref id="b27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallan</surname><given-names>SI</given-names></name><name><surname>Dahl</surname><given-names>K</given-names></name><name><surname>Oien</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey.</article-title><source>BMJ</source><year>2006</year><volume>333</volume><issue>7577</issue><fpage>1047</fpage><pub-id pub-id-type="pmid">17062598</pub-id></element-citation></ref><ref id="b28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moynihan</surname><given-names>R</given-names></name><name><surname>Glassock</surname><given-names>R</given-names></name><name><surname>Doust</surname><given-names>J</given-names></name></person-group><article-title>Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased.</article-title><source>BMJ</source><year>2013</year><volume>347</volume><fpage>f4298</fpage><pub-id pub-id-type="pmid">23900313</pub-id></element-citation></ref><ref id="b29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallan</surname><given-names>SI</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><name><surname>Sang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Age and association of kidney measures with mortality and end-stage renal disease</article-title><source>JAMA</source><year>2012</year><volume>308</volume><issue>22</issue><fpage>2349</fpage><lpage>2360</lpage><pub-id pub-id-type="pmid">23111824</pub-id></element-citation></ref><ref id="b30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Hare</surname><given-names>AM</given-names></name><name><surname>Bertenthal</surname><given-names>D</given-names></name><name><surname>Covinsky</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Mortality risk stratification in chronic kidney disease: one size for all ages?</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><issue>3</issue><fpage>846</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">16452492</pub-id></element-citation></ref><ref id="b31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksen</surname><given-names>BO</given-names></name><name><surname>Ingebretsen</surname><given-names>OC</given-names></name></person-group><article-title>In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression</article-title><source>Kidney Int</source><year>2007</year><volume>72</volume><issue>10</issue><fpage>1242</fpage><lpage>1248</lpage><pub-id pub-id-type="pmid">17687256</pub-id></element-citation></ref></ref-list></back></article>